Author Profile

Kemi Olugemo MD
First Name
Kemi
Last Name
Olugemo
Bio
Kemi Olugemo is a Neuroscience Researcher and Healthcare Advocate. Over her two decades in clinical research and practice, Kemi has been involved in all phases of drug development and global medical strategy. Kemi draws on a diverse set of experiences, including being the current Director of Communications at Women of Color in Pharma (WOCIP), serving on the Scientific Committee of the International Society for CNS Clinical Trials and Methodology (ISCTM), and founding a healthcare nonprofit organization called Zebulon Foundation, Inc.
Country
United States
Qualification
Doctor of Medicine
University Attended
University of Maryland School of Medicine
Graduated Year
2024-02-23
Fields of Interest
Clinical research, health equity, professional development, non-profits
Name
Zebulon Foundation, Inc.
Website Link
https://zebulonfoundation.org/
Contact Email
kemi.olugemo@zebulonfoundation.org
About
Zebulon Foundation is a 501(c)(3) entity created to close gaps in indigent healthcare in West Africa through culturally competent healthcare providers. The organization is volunteer led with leaders representing Nigeria, Ghana, New Zealand, Ireland and the United States.
1 year ago no Comment

Some view the COVID-19 pandemic as a reputational turning point for pharma and an opportunity to solidify a more positive impact on society. Many pharmaceutical companies are furthering this goal by incorporating ESG into their operations.

1 year ago no Comment

The United States continues to face a growing obesity epidemic. The number of people living with excess weight has tripled since 1975, standing at 39% of the American population. Carrying extra pounds is linked with lifelong illnesses such as cardiovascular disease, diabetes, and cancer.

Free Account for Medical Professionals
If you're a medical professional or part of the medical industry, please select this Membership. You will enjoy full access to the platform and be abl...
Kemi Olugemo MD does not have any friends yet.